An update on the management of aspirin-exacerbated respiratory disease

References

• Kowalski ML, Asero R, Bavbek S, et al. Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy. 2013;68(10):1219–1232.
   PubMed Web of Science ®Google Scholar
• Le Pham D, Lee JH, Park HS. Aspirin-exacerbated respiratory disease: an update. Curr Opin Pulm Med. 2017;23(1):89–96.
   PubMed Web of Science ®Google Scholar
• Bochenek G, Kuschill-Dziurda J, Szafraniec K, et al. Certain subphenotypes of aspirin-exacerbated respiratory disease distinguished by latent class analysis. J Allergy Clin Immunol. 2014;133(1):98–103.
   PubMed Web of Science ®Google Scholar
• Hayashi H, Mitsui C, Nakatani E, et al. Omalizumab reduces cysteinyl leukotriene and 9alpha,11beta-prostaglandin F2 overproduction in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2016;137(5):1585–1587.
   PubMed Web of Science ®Google Scholar
• Rajan JP, Wineinger NE, Stevenson DD, et al. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature. J Allergy Clin Immunol. 2015;135(3):676–681.
   PubMed Web of Science ®Google Scholar
• Blanca-Lopez N, Haroun-Diaz E, Ruano FJ, et al. Acetyl salicylic acid challenge in children with hypersensitivity reactions to nonsteroidal anti-inflammatory drugs differentiates between cross-intolerant and selective responders. J Allergy Clin Immunol Pract. 2017:10. DOI:10.1016/j.jaip.2017.08.029
   Google Scholar
• Johns CB, Laidlaw TM. Elevated total serum IgE in nonatopic patients with aspirin-exacerbated respiratory disease. Am J Rhinol Allergy. 2014;28(4):287–289.
   PubMed Web of Science ®Google Scholar
• Lee JY, Kim HM, Ye YM, et al. Role of staphylococcal superantigen-specific IgE antibodies in aspirin-intolerant asthma. Allergy Asthma Proc. 2006;27(5):341–346.
   PubMed Web of Science ®Google Scholar
• Choi JH, Kim JH, Park HS. Upper airways in aspirin-exacerbated respiratory disease. Curr Opin Allergy Clin Immunol. 2015;15(1):21–26.
   PubMed Web of Science ®Google Scholar
• Sanak M. Eicosanoid mediators in the airway inflammation of asthmatic patients: what is new?. Allergy Asthma Immunol Res. 2016;8(6):481–490.
   PubMed Web of Science ®Google Scholar
• Cahill KN, Bensko JC, Boyce JA, et al. Prostaglandin D(2): a dominant mediator of aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2015;135(1):245–252.
   PubMed Web of Science ®Google Scholar
• Jyothula SS, Eissa NT. Autophagy and role in asthma. Curr Opin Pulm Med. 2013;19(1):30–35.
   PubMed Web of Science ®Google Scholar
• Ueki S, Tokunaga T, Fujieda S, et al. Eosinophil ETosis and DNA Traps: a new look at eosinophilic inflammation. Curr Allergy Asthma Rep. 2016;16(8):54.
   PubMed Web of Science ®Google Scholar
• Ban GY, Pham DL, Trinh TH, et al. Autophagy mechanisms in sputum and peripheral blood cells of patients with severe asthma: a new therapeutic target. Clin Exp Allergy. 2016;46(1):48–59.
   PubMed Web of Science ®Google Scholar
• Liu T, Kanaoka Y, Barrett NA, et al. Aspirin-exacerbated respiratory disease involves a cysteinyl leukotriene-driven IL-33-mediated mast cell activation pathway. J Immunol. 2015;195(8):3537–3545.
   PubMed Web of Science ®Google Scholar
• Buchheit KM, Cahill KN, Katz HR, et al. Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2016;137(5):1566–1576.
   PubMed Web of Science ®Google Scholar
• Park H, Choi Y, Jung CG, et al. Potential biomarkers for NSAID-exacerbated respiratory disease. Mediators Inflamm. 2017:8. DOI:10.1155/2017/8160148
   Web of Science ®Google Scholar
• Choi JH, Lee KW, Oh HB, et al. HLA association in aspirin-intolerant asthma: DPB1*0301 as a strong marker in a Korean population. J Allergy Clin Immunol. 2004;113(3):562–564.
   PubMed Web of Science ®Google Scholar
• Kim SH, Oh JM, Kim YS, et al. Cysteinyl leukotriene receptor 1 promoter polymorphism is associated with aspirin-intolerant asthma in males. Clin Exp Allergy. 2006;36(4):433–439.
   PubMed Web of Science ®Google Scholar
• Losol P, Palikhe NS, Lee JW, et al. Association of P2RY12 polymorphisms with eosinophil and platelet activation in patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2015;114(5):423–424.
   PubMed Web of Science ®Google Scholar
• Kim SH, Choi H, Yoon MG, et al. Dipeptidyl-peptidase 10 as a genetic biomarker for the aspirin-exacerbated respiratory disease phenotype. Ann Allergy Asthma Immunol. 2015;114(3):208–213.
   PubMed Web of Science ®Google Scholar
• Dahlin A, Weiss ST. Genetic and epigenetic components of aspirin-exacerbated respiratory disease. Immunol Allergy Clin North Am. 2016;36(4):765–789.
   PubMed Web of Science ®Google Scholar
• Cheong HS, Park SM, Kim MO, et al. Genome-wide methylation profile of nasal polyps: relation to aspirin hypersensitivity in asthmatics. Allergy. 2011;66(5):637–644.
   PubMed Web of Science ®Google Scholar
• Cahill KN, Raby BA, Zhou X, et al. Impaired E prostanoid2 expression and resistance to prostaglandin E2 in nasal polyp fibroblasts from subjects with aspirin-exacerbated respiratory disease. Am J Respir Cell Mol Biol. 2016;54(1):34–40.
   PubMed Web of Science ®Google Scholar
• Yoo HS, Shin YS, Liu JN, et al. Clinical significance of immunoglobulin E responses to staphylococcal superantigens in patients with aspirin-exacerbated respiratory disease. Int Arch Allergy Immunol. 2013;162(4):340–345.
   PubMed Web of Science ®Google Scholar
• Laidlaw TM, Kidder MS, Bhattacharyya N, et al. Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes. Blood. 2012;119(16):3790–3798.
   PubMed Web of Science ®Google Scholar
• Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin-induced asthma. AIANE Investigators. European network on aspirin-induced asthma. Eur Respir J. 2000;16(3):432–436.
   PubMed Web of Science ®Google Scholar
• Ledford DK, Wenzel SE, Lockey RF. Aspirin or other nonsteroidal inflammatory agent exacerbated asthma. J Allergy Clin Immunol Pract. 2014;2(6):653–657.
   PubMed Web of Science ®Google Scholar
• Nizankowska-Mogilnicka E, Bochenek G, Mastalerz L, et al. EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity. Allergy. 2007;62(10):1111–1118.
   PubMed Web of Science ®Google Scholar
• Lee RU, Stevenson DD. Aspirin-exacerbated respiratory disease: evaluation and management. Allergy Asthma Immunol Res. 2011;3(1):3–10.
   PubMed Web of Science ®Google Scholar
• White A, Ludington E, Mehra P, et al. Effect of leukotriene modifier drugs on the safety of oral aspirin challenges. Ann Allergy Asthma Immunol. 2006;97(5):688–693.
   PubMed Web of Science ®Google Scholar
• Dursun AB, Woessner KA, Simon RA, et al. Predicting outcomes of oral aspirin challenges in patients with asthma, nasal polyps, and chronic sinusitis. Ann Allergy Asthma Immunol. 2008;100(5):420–425.
   PubMed Web of Science ®Google Scholar
• Miller B, Mirakian R, Gane S, et al. Nasal lysine aspirin challenge in the diagnosis of aspirin - exacerbated respiratory disease: asthma and rhinitis. Clin Exp Allergy. 2013;43(8):874–880.
   PubMed Web of Science ®Google Scholar
• Pierzchalska M, Mastalerz L, Sanak M, et al. A moderate and unspecific release of cysteinyl leukotrienes by aspirin from peripheral blood leucocytes precludes its value for aspirin sensitivity testing in asthma. Clin Exp Allergy. 2000;30(12):1785–1791.
   PubMed Web of Science ®Google Scholar
• De Weck AL, Sanz ML, Gamboa PM, et al. Nonsteroidal anti-inflammatory drug hypersensitivity syndrome: a multicenter study. II. Basophil activation by nonsteroidal anti-inflammatory drugs and its impact on pathogenesis. J Investig Allergol Clin Immunol. 2010;20(1):39–57.
   PubMed Web of Science ®Google Scholar
• Kim MA, Izuhara K, Ohta S, et al. Association of serum periostin with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2014;113(3):314–320.
   PubMed Web of Science ®Google Scholar
• Ban GY, Cho K, Kim SH, et al. Metabolomic analysis identifies potential diagnostic biomarkers for aspirin-exacerbated respiratory disease. Clin Exp Allergy. 2017;47(1):37–47.
   PubMed Web of Science ®Google Scholar
• Choi GS, Kim JH, Shin YS, et al. Eosinophil activation and novel mediators in the aspirin-induced nasal response in AERD. Clin Exp Allergy. 2013;43(7):730–740.
   PubMed Web of Science ®Google Scholar
• Jerschow E, Ren Z, Hudes G, et al. Utility of low-dose oral aspirin challenges for diagnosis of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2016;116(4):321–328.
   PubMed Web of Science ®Google Scholar
• Pham DL, Kim JH, Trinh TH, et al. What we know about nonsteroidal anti-inflammatory drug hypersensitivity. Korean J Intern Med. 2016;31(3):417–432.
   PubMed Web of Science ®Google Scholar
• Buchheit KM, Laidlaw TM. Update on the management of aspirin-exacerbated respiratory disease. Allergy Asthma Immunol Res. 2016;8(4):298–304.
   PubMed Web of Science ®Google Scholar
• Kim YJ, Lim KH, Kim MY, et al. Cross-reactivity to acetaminophen and celecoxib according to the type of nonsteroidal anti-inflammatory drug hypersensitivity. Allergy Asthma Immunol Res. 2014;6(2):156–162.
   PubMed Web of Science ®Google Scholar
• Baldassarre S, Schandene L, Choufani G, et al. Asthma attacks induced by low doses of celecoxib, aspirin, and acetaminophen. J Allergy Clin Immunol. 2006;117(1):215–217.
   PubMed Web of Science ®Google Scholar
• Munoz-Cano R, Bartra J, Vennera MC, et al. Asthmatic reaction induced by celecoxib in a patient with aspirin-induced asthma. J Investiq Allergol Clini Immunol. 2009;19(1):75–76.
   PubMed Web of Science ®Google Scholar
• Koschel D, Weber CN, Hoffken G. Tolerability to etoricoxib in patients with aspirin-exacerbated respiratory disease. J Investiq Allergol Clini Immunol. 2013;23(4):275–280.
   PubMed Web of Science ®Google Scholar
• Morales DR, Lipworth BJ, Guthrie B, et al. Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2 inhibitors: meta-analysis of controlled clinical trials. J Allergy Clin Immunol. 2014;134(1):40–45.
   PubMed Web of Science ®Google Scholar
• Global initiative for asthma [Internet]. 2017. GINA report, global strategy for asthma management and prevention. [cited 2017 Oct 9]. Available from: www.ginasthma.org.
   Google Scholar
• Trinh HK, Ban GY, Lee JH, et al. Leukotriene receptor antagonists for the treatment of asthma in elderly patients. Drugs Aging. 2016;33(10):699–710.
   PubMed Web of Science ®Google Scholar
• Dahlen SE, Malmstrom K, Nizankowska E, et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165(1):9–14.
   PubMed Web of Science ®Google Scholar
• Cho KS, Soudry E, Psaltis AJ, et al. Long-term sinonasal outcomes of aspirin desensitization in aspirin exacerbated respiratory disease. Otolaryngol Head Neck Surg. 2014;151(4):575–581.
   PubMed Web of Science ®Google Scholar
• Berges-Gimeno MP, Simon RA, Stevenson DD. Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2003;111(1):180–186.
   PubMed Web of Science ®Google Scholar
• Li J, Kang J, Wang C, et al. Omalizumab improves quality of life and asthma control in Chinese patients with moderate to severe asthma: a randomized phase III study. Allergy Asthma Immunol Res. 2016;8(4):319–328.
   PubMed Web of Science ®Google Scholar
• Gevaert P, Calus L, Van Zele T, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013;131(1):110–116.
   PubMed Web of Science ®Google Scholar
• Garcia G, Magnan A, Chiron R, et al. A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma. Chest. 2013;144(2):411–419.
   PubMed Web of Science ®Google Scholar
• Pillai P, Chan YC, Wu SY, et al. Omalizumab reduces bronchial mucosal IgE and improves lung function in non-atopic asthma. Eur Respir J. 2016;48(6):1593–1601.
   PubMed Web of Science ®Google Scholar
• Gevaert P, Van Bruaene N, Cattaert T, et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol. 2011;128(5):989–995.
   PubMed Web of Science ®Google Scholar
• Farne HA, Wilson A, Powell C, et al. Anti-IL5 therapies for asthma. Cochrane Database Syst Rev. 2017;9:CD010834.
   PubMed Web of Science ®Google Scholar
• Park HS, Kim MK, Imai N, et al. A phase 2a study of benralizumab for patients with eosinophilic asthma in South Korea and Japan. Int Arch Allergy Immunol. 2016;169(3):135–145.
   PubMed Web of Science ®Google Scholar
• Pettipher R, Hunter MG, Perkins CM, et al. Heightened response of eosinophilic asthmatic patients to the CRTH2 antagonist OC000459. Allergy. 2014;69(9):1223–1232.
   PubMed Web of Science ®Google Scholar